Skip to main content
Top
Published in: Abdominal Radiology 3/2009

01-06-2009

Can MRCP replace ERCP for the diagnosis of autoimmune pancreatitis?

Authors: T. Kamisawa, Y. Tu, N. Egawa, K. Tsuruta, A. Okamoto, M. Kodama, N. Kamata

Published in: Abdominal Radiology | Issue 3/2009

Login to get access

Abstract

Background

It is of utmost importance that autoimmune pancreatitis (AIP) be differentiated from pancreatic cancer. Irregular narrowing of the main pancreatic duct is a characteristic finding in AIP; it is useful for differentiating AIP from pancreatic cancer stenosis. This study evaluated the usefulness of magnetic resonance cholangiopancreatography (MRCP) for the diagnosis of AIP and assessed whether MRCP could replace endoscopic retrograde cholangiopancreatography (ERCP) for diagnosing AIP.

Methods

The MRCP and ERCP findings of 20 AIP patients were compared.

Results

On MRCP, the narrowed portion of the main pancreatic duct was not visualized, while the noninvolved segments of the pancreatic duct were visualized. The degree of upstream dilatation of the proximal main pancreatic duct was milder in AIP than in pancreatic cancer patients. In the skipped type, only skipped narrowed lesions were not visualized. After steroid therapy for AIP, the nonvisualized main pancreatic duct became visualized.

Conclusions

MRCP cannot replace ERCP for the diagnosis of AIP, since narrowing of the main pancreatic duct in AIP was not visualized on MRCP. MRCP findings of segmental or skipped nonvisualized main pancreatic duct accompanied by a less dilated upstream main pancreatic duct may suggest the presence of AIP. MRCP is useful for following AIP patients.
Literature
1.
go back to reference Yoshida K, Toki F, Takeuchi T, et al. (1995) Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 40:1561–1568PubMedCrossRef Yoshida K, Toki F, Takeuchi T, et al. (1995) Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 40:1561–1568PubMedCrossRef
2.
go back to reference Kamisawa T, Okamoto A (2006) Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 41:613–625PubMedCrossRef Kamisawa T, Okamoto A (2006) Autoimmune pancreatitis: proposal of IgG4-related sclerosing disease. J Gastroenterol 41:613–625PubMedCrossRef
3.
go back to reference Okazaki K, Kawa S, Kamisawa T, et al., Research Committee of Intractable Diseases of the Pancreas (2006) Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol 41:626–631PubMedCrossRef Okazaki K, Kawa S, Kamisawa T, et al., Research Committee of Intractable Diseases of the Pancreas (2006) Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal. J Gastroenterol 41:626–631PubMedCrossRef
4.
go back to reference Sica GT, Braver J, Cooney MJ, et al. (1999) Comparison of endoscopic retrograde cholangiopancreatography with MR cholangiopancreatography in patients with pancreatitis. Radiology 210:605–610PubMed Sica GT, Braver J, Cooney MJ, et al. (1999) Comparison of endoscopic retrograde cholangiopancreatography with MR cholangiopancreatography in patients with pancreatitis. Radiology 210:605–610PubMed
6.
go back to reference Kamisawa T, Chen PY, Tu Y, et al. (2006) MRCP and MRI findings in 9 patients with autoimmune pancreatitis. World J Gastroenterol 12:2919–2922PubMed Kamisawa T, Chen PY, Tu Y, et al. (2006) MRCP and MRI findings in 9 patients with autoimmune pancreatitis. World J Gastroenterol 12:2919–2922PubMed
7.
go back to reference Kamisawa T, Egawa N, Nakajima H, et al. (2003) Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol 98:2694–2699PubMedCrossRef Kamisawa T, Egawa N, Nakajima H, et al. (2003) Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am J Gastroenterol 98:2694–2699PubMedCrossRef
8.
go back to reference Hardacre JM, Iacobuzio-Donahue CA, Sohn TA, et al. (2003) Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis. Ann Surg 237:853–859PubMedCrossRef Hardacre JM, Iacobuzio-Donahue CA, Sohn TA, et al. (2003) Results of pancreaticoduodenectomy for lymphoplasmacytic sclerosing pancreatitis. Ann Surg 237:853–859PubMedCrossRef
9.
go back to reference Kim KP, Kim MH, Kim JC, et al. (2006) Diagnostic criteria for autoimmune chronic pancreatitis revised. World J Gastroenterol 12:2487–2496PubMed Kim KP, Kim MH, Kim JC, et al. (2006) Diagnostic criteria for autoimmune chronic pancreatitis revised. World J Gastroenterol 12:2487–2496PubMed
10.
go back to reference Freeny P, Bilbao M, Katon R (1976) Blind evaluation of endoscopic retrograde cholangiopancreatography (ERCP) in the diagnosis of pancreatic carcinoma: the “double duct” and other signs. Radiology 119:271–274PubMed Freeny P, Bilbao M, Katon R (1976) Blind evaluation of endoscopic retrograde cholangiopancreatography (ERCP) in the diagnosis of pancreatic carcinoma: the “double duct” and other signs. Radiology 119:271–274PubMed
11.
go back to reference Menges M, Lerch MM, Zeitz M (2000) The double duct sign in patients with malignant and benign pancreatic lesions. Gastrointest Endosc 52:74–77PubMedCrossRef Menges M, Lerch MM, Zeitz M (2000) The double duct sign in patients with malignant and benign pancreatic lesions. Gastrointest Endosc 52:74–77PubMedCrossRef
Metadata
Title
Can MRCP replace ERCP for the diagnosis of autoimmune pancreatitis?
Authors
T. Kamisawa
Y. Tu
N. Egawa
K. Tsuruta
A. Okamoto
M. Kodama
N. Kamata
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Abdominal Radiology / Issue 3/2009
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-008-9401-y

Other articles of this Issue 3/2009

Abdominal Radiology 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine